Market Place
Sourcing Support
Sparrow Pharmaceuticals Presents at ACR 2024, Expands Phase 2 Study
14 Nov 2024 //
BUSINESSWIRE
Sparrow Pharma Completes Ph 2 Trial for Cushing’s Syndrome
28 Oct 2024 //
BUSINESSWIRE
Sparrow Pharmaceuticals Presented New Data On Clofutriben
19 Sep 2024 //
BUSINESSWIRE
Sparrow Presents Clofutriben Data In PMR At EULAR 2024
14 Jun 2024 //
BUSINESSWIRE
Sparrow Presenting On Clofutriben For Polymyalgia At EU Rheumatology
07 Jun 2024 //
BUSINESSWIRE
Sparrow To Present On Clofutriben For Polymyalgia At EU Rheumatology Congress
06 Jun 2024 //
BUSINESSWIRE
Sparrow Pharma: Novel Clofutriben Data Reduces Glucocorticoid Toxicity
04 Jun 2024 //
BUSINESSWIRE
Sparrow`s David Katz To Receive Innovation Award At Endocrine Society
30 May 2024 //
BUSINESSWIRE
Sparrow Pharmaceuticals Doses First Patient in Phase 2 ACSpire Study of SPI-62
24 Oct 2023 //
BUSINESSWIRE
Sparrow Pharmaceuticals Initiates Third Cohort in PROST!
12 Sep 2023 //
BUSINESSWIRE
Sparrow Announces First Patient Rolled-Over to Open-Label Extension of RESCUE
16 Aug 2023 //
BUSINESSWIRE
ICR Hosts Sparrow Pharmaceuticals on the Welcome to the Arena Podcast
14 Jun 2023 //
BUSINESSWIRE
Sparrow to Present on HSD-1 Inhibitor SPI-62 at Endocrine Society Conference
08 Jun 2023 //
BUSINESSWIRE
Sparrow Presents ePoster on SPI-62 at 25th European Congress of Endocrinology
13 May 2023 //
BUSINESSWIRE
Sparrow Pharma Expands Phase 2 Clinical Trial of SPI-62 with Prednisolone
08 Mar 2023 //
BUSINESSWIRE
Sparrow Pharmaceuticals Presents Pharmacology Data on SPI-62
14 Nov 2022 //
BUSINESSWIRE
Sparrow Pharmaceuticals Announces First Patient Dosed in RESCUE
28 Sep 2022 //
BUSINESSWIRE
Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62
09 Sep 2022 //
BUSINESSWIRE
Sparrow Pharma Presents Trial Data Analyses on HSD-1 Inhibitor SPI-62 at ENDO
14 Jun 2022 //
BUSINESSWIRE
Sparrow Pharma to Present New Clinical Pharmacology Data on SPI-62 at ENDO
10 Jun 2022 //
BUSINESSWIRE
Sparrow Pharma Presents New Pharmacological Data on SPI-62
03 Jun 2022 //
BUSINESSWIRE
Sparrow Pharma to Present New Pharmacology Data on SPI-62 at the 2022 ECR
01 Jun 2022 //
BUSINESSWIRE
Sparrow Pharma Presents New Trial Data Analyses on HSD-1 Inhibitor SPI-62
24 May 2022 //
BUSINESSWIRE
Sparrow Pharmaceuticals to Present New Clinical Pharmacology Data on SPI-62
17 May 2022 //
BUSINESSWIRE
FDA Clears Sparrow`s IND for SPI-62 in Cushing’s Disease
13 Dec 2021 //
BUSINESSWIRE
Sparrow Pharmaceuticals appoints Frank Czerwiec, CMO and Jamie MacPherson, VP.
17 Aug 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.